PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming‐Sound Tsao, Keith M. Kerr, Mark M. Kockx et al. · Journal of Thoracic Oncology · 2018
Cited by 794 works. doi:10.1016/j.jtho.2018.05.013 Open-access PDF
Authors
- Ming‐Sound Tsao
- Keith M. Kerr
- Mark M. Kockx
- Mary Beth Beasley
- Alain Borczuk
- Johan Botling
- Lukas Bubendorf
- Lucian R. Chirieac
- Gang Chen
- Teh‐Ying Chou
- Jin-Haeng Chung
- Sanja Đačić
- Sylvie Lantuéjoul
- Mari A. Mino-Kenudson
- Andre Luis Moreira
- Andrew Gordon Nicholson
- Masayuki Noguchi
- Giuseppe Pelosi
- Claudia Poleri
- Prudence Anne Russell
References
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
- A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research
- Interrater reliability: the kappa statistic
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- PD-L1 Expression in Lung Cancer
- Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer